Kantos Nexthaler

Beclometasone dipropionate / Formoterol fumarate, the active ingredient in Kantos Nexthaler, is an inhaled corticosteroid/long‑acting β2‑agonist combination presented as a dry powder inhaler for inhalation use. It treats asthma and chronic obstructive pulmonary disease as maintenance therapy in adults and children.

GNH USA supplies Kantos Nexthaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kantos Nexthaler combines an inhaled corticosteroid and a long‑acting β2‑agonist to provide maintenance control of obstructive airway diseases.

Asthma: improves long‑term symptom control and reduces exacerbations. COPD: maintains airway patency, decreases breathlessness and lowers risk of flare‑ups. Bronchial hyper‑responsiveness: reduces airway inflammation and reactivity. Reversible airway obstruction: provides sustained bronchodilation and anti‑inflammatory effect.

Common Side Effects: - Throat irritation or hoarseness. - Cough after inhalation. - Oral candidiasis (thrush). - Headache. - Nasopharyngitis.

Serious or Rare Side Effects: - Paradoxical bronchospasm. - Adrenal suppression with prolonged high‑dose use. - Severe allergic reaction such as anaphylaxis. - Cardiac arrhythmias or tachycardia. - Pneumonia, especially in COPD patients.

Before prescribing Kantos Nexthaler, clinicians should consider the following precautions. - Assess asthma or COPD control before initiating: ensure patient has an appropriate rescue inhaler. - Monitor for oral thrush: advise rinsing mouth after each dose. - Avoid abrupt discontinuation: may lead to worsening symptoms. - Use with caution in patients with cardiovascular disease: monitor heart rate and blood pressure. - Store at ambient temperature below 25°C: keep in original pack, protect from moisture.

Kantos Nexthaler may interact with other medicines; awareness of interaction severity is important.

Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator effect. - MAO inhibitors: potential for hypertensive crisis with formoterol. - Diuretics: may increase risk of hypokalemia.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise systemic corticosteroid exposure. - Ritonavir: can increase formoterol plasma levels. - Theophylline: may enhance stimulant effects, requiring monitoring.